RHY 0.00% 6.1¢ rhythm biosciences limited

Rhy: Proxy forms., page-4

  1. 709 Posts.
    lightbulb Created with Sketch. 649
    Your support for Otto, despite the evident performance issues and strategic missteps during his tenure, appears unusual. It's surprising to see a dismissal of valid concerns and a resistance to acknowledging the market standard is greater accountability for someone appointed as an executive for their commercialisation experience. Someone with R&D, Company Secretary or other experience doesnt carry equal weight for commercialisation strategy failings. The requisitioning shareholders have presented compelling points advocating for change, and it would be beneficial to approach this discussion without emotive and condescending language i.e., "ridiculous and extremely naive". What is arguably ridiculous and extremely naive is following the boards recommendation blindly. This can sometomes be achieved when an executive positions that they're all equally responsible but its just not accurate and this victim like behaviour is helping nobody. In the public sector, an executive who had come in for commercialisation is typically held accountable and may step aside willingly when faced with significant failures. Given Mr. Buttula's extended tenure and apparent lack of accountability despite no timely strategic pivots, the requisitioning shareholders' call for fresh leadership deserves thoughtful consideration rather than following the depleted boards recommendation blindly or "naively".
    Last edited by 88888acct: 13/01/24
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
(20min delay)
Last
6.1¢
Change
0.000(0.00%)
Mkt cap ! $15.16M
Open High Low Value Volume
6.1¢ 6.1¢ 6.1¢ $1.448K 23.74K

Buyers (Bids)

No. Vol. Price($)
2 124000 6.0¢
 

Sellers (Offers)

Price($) Vol. No.
6.6¢ 79998 1
View Market Depth
Last trade - 15.43pm 17/07/2024 (20 minute delay) ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.